Literature DB >> 9334922

Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b.

W T Hofgärtner1, S J Polyak, D G Sullivan, R L Carithers, D R Gretch.   

Abstract

Previous studies from Japan have described an association between a conserved sequence within the hepatitis C virus (HCV) genome and resistance to interferon (IFN) therapy for patients infected with HCV genotype 1b [Enomoto et al. (1995): Journal of Clinical Investigation 96: 224-230; Enomoto et al. (1996): New England Journal of Medicine 334:77-81]. The present study examines amino acid sequences surrounding the putative Interferon Sensitivity Determining Region (ISDR) of the NS5A gene of HCV in 21 North American patients with genotype 1a or 1b infection receiving recombinant IFN therapy. The ISDR consensus or intermediate pattern was observed in 13 of 14 NS5A clones from North American patients infected with genotype 1b. However, we found no evidence of the consensus ISDR sequence in any NS5A clones isolated from 15 patients with genotype 1a infection. In select cases, gel shift analysis showed no significant changes in the clonal frequency of the putative ISDR domain of HCV genotype 1a or 1b infected patients who were either nonresponsive to IFN therapy, or relapsed following withdrawal of IFN therapy. These results suggest that a conserved ISDR domain is neither associated with, nor responsible for, IFN resistance in North American patients infected with HCV genotype 1a, and demonstrate a need for further investigation into the reported association between ISDR consensus sequences and IFN resistance in genotype 1b clones.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9334922     DOI: 10.1002/(sici)1096-9071(199710)53:2<118::aid-jmv3>3.0.co;2-c

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  28 in total

1.  Management of chronic hepatitis C and prevention of hepatocellular carcinoma.

Authors:  Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

2.  Mutations around interferon sensitivity-determining region: a pilot resistance report of hepatitis C virus 1b in a Hong Kong population.

Authors:  Xiao-Ming Zhou; Paul Ks Chan; John S Tam
Journal:  World J Gastroenterol       Date:  2011-12-28       Impact factor: 5.742

3.  Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes.

Authors:  Catherine A Lázaro; Ming Chang; Weiliang Tang; Jean Campbell; Daniel G Sullivan; David R Gretch; Lawrence Corey; Robert W Coombs; Nelson Fausto
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

4.  Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome.

Authors:  Patrizia Farci; Rita Strazzera; Harvey J Alter; Stefania Farci; Daniela Degioannis; Alessandra Coiana; Giovanna Peddis; Francesco Usai; Giancarlo Serra; Luchino Chessa; Giacomo Diaz; Angelo Balestrieri; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-05       Impact factor: 11.205

Review 5.  Impact of host and virus genome variability on HCV replication and response to interferon.

Authors:  Cameron J Schweitzer; T Jake Liang
Journal:  Curr Opin Virol       Date:  2013-07-06       Impact factor: 7.090

6.  Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection.

Authors:  Mina Nakagawa; Naoya Sakamoto; Mayumi Ueyama; Kaoru Mogushi; Satoshi Nagaie; Yasuhiro Itsui; Seishin Azuma; Sei Kakinuma; Hiroshi Tanaka; Nobuyuki Enomoto; Mamoru Watanabe
Journal:  J Gastroenterol       Date:  2010-01-30       Impact factor: 7.527

Review 7.  Hepatitis C genotype 6: A concise review and response-guided therapy proposal.

Authors:  Chalermrat Bunchorntavakul; Disaya Chavalitdhamrong; Tawesak Tanwandee
Journal:  World J Hepatol       Date:  2013-09-27

8.  Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy.

Authors:  J Nousbaum; S J Polyak; S C Ray; D G Sullivan; A M Larson; R L Carithers; D R Gretch
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

9.  Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system.

Authors:  Ana Maria Contreras; Yoichi Hiasa; Wenping He; Adam Terella; Emmett V Schmidt; Raymond T Chung
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

Review 10.  Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C.

Authors:  Shinya Maekawa; Nobuyuki Enomoto
Journal:  J Gastroenterol       Date:  2009       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.